Linking pharmacogenetics-based diagnostics and drugs for personalized medicine

Health Affairs

Volumn 25, Issue 5, 2006, Pages 1281-1290

  Garrison Jr , Louis P ^a   Austin, M J Finley ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

BIOTECHNOLOGY; DRUG DESIGN; HUMAN; MASS COMMUNICATION; PHARMACOGENETICS; REVIEW; UNITED STATES;

BIOLOGICAL MARKERS; BIOTECHNOLOGY; DIFFUSION OF INNOVATION; DRUG DESIGN; HUMANS; PHARMACOGENETICS; UNITED STATES;

EID: 33749334735     PISSN: 02782715     EISSN: 02782715     Source Type: Journal    
DOI: 10.1377/hlthaff.25.5.1281     Document Type: Review

References (16)

1. Royal Society, Personalised Medicine: Hopes and Realities, September 2005, http://www.royalsoc.ac.uk/displaypagedoc.asp?id=17570 (accessed 31 May 2006).
2. R.M. Califf, "Defining the Balance of Risk and Benefit in the Era of Genomics and Proteomics," Health Affairs 23, no. 1 (2004): 77-87.
3. S.H. Ralston et al., "Large-Scale Evidence for the Effect of the COLIA1 Sp1 Polymorphism on Osteoporosis Outcomes: The GENOMOS Study," PLoS Medicine 3, no. 4 (2006): e90.
4. D. Boomsma, A. Busjahn, and L. Peltonen, "Classical Twin Studies and Beyond," Nature Reviews Genetics 3, no. 11 (2002): 872-882.
5. Y. Gasche et al., "Codeine Intoxication Associated with Ultrarapid CYP2D6 Metabolism," New England Journal of Medicine 351, no. 27 (2004): 2827-2831.
6. Centers for Disease Control and Prevention, "ACCE: A CDC-Sponsored Project Carried Out by the Foundation of Blood Research," 1 June 2006, http://www.cdc.gov/genomics/gtesting/ACCE.htm (accessed 12 June 2006).
7. D.W. Bell et al., "Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non-Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials," Journal of Clinical Oncology 23, no. 31 (2005): 8081-8092.
8. J.A. Hirschhorn et al., "A Comprehensive Review of Genetic Association Studies," Genetics in Medicine 4, no. 2 (2002): 45-61.
9. J.A. DiMasi and C. Paquette, "The Economics of Follow-On Drug Research and Development: Trends in the Entry Rates and the Timing of Development," PharmacoEconomics 22, no. 2 Supp. (2004): 1-14.
10. H. Grabowski, J. Vernon, and J.A. DiMasi, "Returns on Research and Development for 1990s New Drug Introductions," PharmacoEconomics 20, no. 3 Supp. (2002): 11-29.
11. P.M. Danzon and A. Towse, "Differential Pricing for Pharmaceuticals: Reconciling Access, R&D, and Patents," International Journal of Health Care Finance and Economics 3, no. 3 (2003): 183-205.
12. Lewin Group, The Value of Diagnostics: Innovation, Adoption and Diffusion into Health Care, Report prepared for AdvaMed, July 2005, http://www.advamed. org/publicdocs/thevalueofdiagnostics.pdf (accessed 31 May 2006). In France and Germany, price and reimbursement are set by national committees; in the United Kingdom, prices are negotiated between labs and manufacturers.
13. G.G. Raab and L.J. Logue, "Medicare Coverage of New Clinical Diagnostic Laboratory Tests: The Need for Coding and Payment Reforms," Clinical Leadership and Management Review 15, no. 6 (2001): 376-387.
14. B.B. Spear, M. Heath-Chiozzi, and J. Huff, "Clinical Application of Pharmacogenetics," Trends in Molecular Medicine 7, no. 5 (2001): 201-204.
15. L.P. Garrison and M.J.F. Austin, "The Economics of Personalized Medicine: A Model of Incentives for Value Creation and Capture" (Unpublished paper, March 2006).
16. S.D. Ramsey et al., "Toward Evidence-based Assessment for Coverage and Reimbursement of Laboratory-based Diagnostic and Genetic Tests," American Journal of Managed Care 12, no. 4 (2006): 197-202.